Trial literature on neuroblastoma

Last modification: 2017/01/05

Literature on neuroblastoma trials


  1. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS: Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European journal of cancer (Oxford, England : 1990) 2016, 65: 1 [PMID: 27434878] MOR2016
  2. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR: Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric blood & cancer 2014, [PMID: 25044743] MEA2014
  3. Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F: Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013, 31: 752 [PMID: 23284039] SIM2013
  4. Simon T, Niemann CA, Hero B, Henze G, Suttorp M, Schilling FH, Berthold F: Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Developmental medicine and child neurology 2012, 54: 347 [PMID: 22329756] SIM2012
  5. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14. 18 or oral metronomic chemotherapy. BMC Cancer 2011, 18; 11: 21. [PMID: 21244693] SIM2011a
  6. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B: Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56: 578 [PMID: 21298742] SIM2011
  7. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H: Dosimetry for (131)I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. European journal of nuclear medicine and molecular imaging 2010, [PMID: 20179922] SUD2010
  8. Fischer M, Bauer T, Oberthür A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B, König R, Berthold F: Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010, 29: 865 [PMID: 19901960] FIS2010
  9. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force: The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 298 [PMID: 19047290] MON2009
  10. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 289 [PMID: 19047291] COH2009
  11. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M: Molecular characterization and classification of neuroblastoma. Future oncology (London, England) 2009, 5: 625 [PMID: 19519203] OBE2009
  12. Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. British journal of cancer 2009, 101: 1481 [PMID: 19707195] HOE2009
  13. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clinical chemistry 2009, 55: 1316 [PMID: 19460840] STU2009
  14. Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F: Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma How much diagnostic imaging is necessary? European journal of radiology 2009, [PMID: 19369017] BEN2009
  15. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma. BMC molecular biology 2009, 10: 28 [PMID: 19348682] VOT2009
  16. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, Niggli F, Schilling F, Schwab M, Simon T, Westermann F, Berthold F, Hero B: Heterogeneity of the MYCN oncogene in neuroblastoma. Clinical cancer research 2009, 15: 2085 [PMID: 19276282] THE2009
  17. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome biology 2008, 9:R150 [PMID: 18851746] WES2008
  18. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D: MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Molecular oncology 2008, 2: 261 [PMID: 19383347] BEN2008
  19. Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M: Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14: 6590 [PMID: 18927300] OBE2008
  20. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. Journal of clinical oncology 2008, 26: 5443 [PMID: 18838715] STU2008
  21. Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F: Risk estimation of neuroblastoma patients using molecular markers. Klinische Padiatrie 2008, 220: 137 [PMID: 18478485] FIS2008
  22. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F: Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. Journal of clinical oncology 2008, 26: 1504 [PMID: 18349403] HER2008
  23. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Molecular cancer research : MCR 2007, 5: 1276 [PMID: 18171985] VOT2007
  24. Simon T, Längler A, Berthold F, Klingebiel T, Hero B: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2007, 29: 101 [PMID: 17279006] SIM2007
  25. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H: Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin. Nuclear medicine 2006, 45: 145-51; quiz N39 [PMID: 16964339] SCH2006b
  26. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer letters 2007, 250: 250 [PMID: 17126996] OBE2006a
  27. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F: Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes, chromosomes & cancer 2006, 45: 1130 [PMID: 16958102] SPI2006a
  28. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24: 5070 [PMID: 17075126] OBE2006
  29. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F: Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12: 5118 [PMID: 16951229] FIS2006
  30. Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F: Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlentherapie und Onkologie 2006, 182: 389 [PMID: 16826357] SIM2006
  31. Spitz R, Hero B, Simon T, Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clinical cancer research 2006, 12(11 Pt 1): 3368 [PMID: 16740759] SPI2006
  32. Schumacher-Kuckelkorn R, Hero B, Ernestus K, Berthold F: Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatric blood & cancer 2005, 45: 195 [PMID: 15800908] SCH2005a
  33. Hero B, Berthold F: Neuroblastoma. In: D. Reinhard (Hrsg.), Leitlinien Kinderheilkunde und Jugendmedizin Urban & Fischer, 2005, L5 1 [ISBN: 3-437-21867-0] HER2005
  34. Fischer M, Skowron M, Berthold F: Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. The Journal of molecular diagnostics 2005, 7: 89 [PMID: 15681479] FIS2005
  35. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F: Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer immunology, immunotherapy : CII 2005, 54: 400 [PMID: 15449039] WOE2005
  36. Eich HT, Muller RP, Micke O, Kocher M, Berthold F, Hero B: Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlentherapie und Onkologie 2005, 181: 378 [PMID: 15925980] EIC2005
  37. Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R: Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Diagnostic molecular pathology 2005, 14: 177 [PMID: 16106200] BOE2005
  38. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The lancet oncology 2005, 6: 649 [PMID: 16129365] BER2005
  39. Simon A, Beutel K, Marklein G, Fleischhack G: Bacterial infections in pediatric cancer patients. Klin Pädiatr 2005, 217 Suppl 1:S17 [PMID: 16288351] SIM2005
  40. Claviez A, Lakomek M, Ritter J, Suttorp M, Kremens B, Dickerhoff R, Harms D, Berthold F, Hero B: Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. European journal of cancer (Oxford, England : 1990) 2004, 40: 2760 [PMID: 15648116] CLA2004c
  41. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F: Consolidation treatment with chimeric anti-GD2-antibody ch14. 18 in children older than 1 year with metastatic neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22: 3549 [PMID: 15337804] SIM2004a
  42. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer research 2004, 64: 6883 [PMID: 15466177] WEI2004a
  43. Jensen M, Tawadros S, Sedlacek HH, Schultze JL, Berthold F: NK cell depletion diminish tumour-specific B cell responses. Immunology letters 2004, 93(2-3): 205 [PMID: 15158618] JEN2004
  44. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F: MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. European journal of cancer (Oxford, England : 1990) 2004, 40: 2753 [PMID: 15571958] SPI2004
  45. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, Michaelis J: Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer letters 2003, 197(1-2): 19 [PMID: 12880955] SCH2003j
  46. Spitz R, Hero B, Ernestus K, Berthold F: Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2003, 9: 4835 [PMID: 14581355] SPI2003d
  47. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer letters 2003, 197(1-2): 11 [PMID: 12880954] BER2003a
  48. Simon T, Hero B, Hunneman DH, Berthold F: Tumour markers are poor predictors for relapse or progression in neuroblastoma. European journal of cancer (Oxford, England : 1990) 2003, 39: 1899 [PMID: 12932669] SIM2003a
  49. Krams M, Heidebrecht HJ, Hero B, Berthold F, Harms D, Parwaresch R, Rudolph P: Repp86 expression and outcome in patients with neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21: 1810 [PMID: 12721258] KRA2003a
  50. Jensen M, Ernestus K, Kemshead J, Klehr M, Von Bergwelt-Baildon MS, Schinkothe T, Schultze JL, Berthold F: The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clinical and experimental immunology 2003, 134: 253 [PMID: 14616785] JEN2003